Contemporary Biology, Management, and Outcomes of Renal Medullary Carcinoma in Children and Adults: A Pediatric Surgical Oncology Research Collaborative Study
- PMID: 40394815
- DOI: 10.1002/pbc.31774
Contemporary Biology, Management, and Outcomes of Renal Medullary Carcinoma in Children and Adults: A Pediatric Surgical Oncology Research Collaborative Study
Abstract
Background: Renal medullary carcinoma (RMC) is an aggressive tumor associated with sickle cell trait. Despite treatment advances for other rare renal tumors, RMC survival remains poor. We aimed to describe the contemporary management and survival of children and adults with RMC.
Procedure: In this multicenter retrospective cohort study, Pediatric Surgical Oncology Research Collaborative sites searched their databases for patients diagnosed with RMC (2000-2022). Descriptive statistics were calculated and survival analyses performed using Kaplan-Meier and Cox regression.
Results: Thirty-four patients with RMC were identified. Median age was 19 years (IQR: 15-28; range: 7-52). Most were male (24/34; 71%), Black (27/32; 84%), had sickle cell trait or disease (30/33; 91%), presented with metastatic disease (27/34; 79%), and were symptomatic at presentation (32/34; 94%). Median overall survival (OS) was 24 months from diagnosis (16 months for children, 28 months for adults, p = 0.6). Receipt of platinum-based chemotherapy (23/34; 68%) was associated with significantly higher OS than other regimens (35 vs. 5 months, p < 0.001). Nephrectomy (24/34; 71%) was associated with significantly improved OS compared with non-operative management (34 vs. 7 months, p = 0.001). Immunotherapy, targeted therapy, or radiation therapy were not associated with significant differences in OS, nor were age, sex, race, sickle cell status, SMARCB1/INI-1, stage, nephrectomy approach, retroperitoneal lymph node dissection, gross residual disease, margins, or tumor size.
Conclusions: RMC survival remains poor despite newer therapies. Nephrectomy and platinum-based chemotherapy should be considered in locally advanced and metastatic disease. Coordinated international cooperative group studies are needed to meaningfully improve RMC survival.
Keywords: pediatric cancer; pediatric surgical oncology; renal cancer; renal medullary carcinoma; sickle cell.
© 2025 Wiley Periodicals LLC.
References
-
- C. J. Davis Jr., F. K. Mostofi, and I. A. Sesterhenn, “Renal Medullary Carcinoma. The Seventh Sickle Cell Nephropathy,” American Journal of Surgical Pathology 19, no. 1 (1995): 1–11, https://doi.org/10.1097/00000478‐199501000‐00001.
-
- K. E. Beckermann, D. Sharma, S. Chaturvedi, et al., “Renal Medullary Carcinoma: Establishing Standards in Practice,” Journal of Oncology Practice 13, no. 7 (2017): 414–421, https://doi.org/10.1200/JOP.2017.020909.
-
- A. Y. Shah, J. A. Karam, G. G. Malouf, et al., “Management and Outcomes of Patients With Renal Medullary Carcinoma: A Multicentre Collaborative Study,” BJU International 120, no. 6 (2017): 782–792, https://doi.org/10.1111/bju.13705.
-
- B. Ezekian, B. Englum, B. F. Gilmore, et al., “Renal Medullary Carcinoma: A National Analysis of 159 Patients,” Pediatric Blood & Cancer 64, no. 11 (2017), e26609, https://doi.org/10.1002/pbc.26609.
-
- R. Iacovelli, D. Modica, A. Palazzo, P. Trenta, G. Piesco, and E. Cortesi, “Clinical Outcome and Prognostic Factors in Renal Medullary Carcinoma: A Pooled Analysis From 18 Years of Medical Literature,” Canadian Urological Association Journal 9, no. 3‐4 (2015): E172–E177, https://doi.org/10.5489/cuaj.2373.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
